615 related articles for article (PubMed ID: 12856513)
21. Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis.
Stepan JJ; Alenfeld F; Boivin G; Feyen JH; Lakatos P
Endocr Regul; 2003 Dec; 37(4):225-38. PubMed ID: 15106819
[TBL] [Abstract][Full Text] [Related]
22. [Effects of SERMs on bone health. Discrimination of SERMs from bisphosphonates in the treatment of postmenopausal osteoporosis].
Iwamoto J
Clin Calcium; 2010 Mar; 20(3):396-407. PubMed ID: 20190370
[TBL] [Abstract][Full Text] [Related]
23. 7: Treatment of osteoporosis: why, whom, when and how to treat. The single most important consideration is the individual's absolute risk of fracture.
Seeman E; Eisman JA
Med J Aust; 2004 Mar; 180(6):298-303. PubMed ID: 15012571
[TBL] [Abstract][Full Text] [Related]
24. Osteoporosis in postmenopausal women. Therapy options across a wide range of risk for fracture.
Miller RG
Geriatrics; 2006 Jan; 61(1):24-30. PubMed ID: 16405361
[TBL] [Abstract][Full Text] [Related]
25. [Therapeutic strategies for osteoporosis].
Chapurlat R; Delmas PD
Ann Med Interne (Paris); 2000 Oct; 151(6):471-6. PubMed ID: 11104926
[TBL] [Abstract][Full Text] [Related]
26. Raloxifene use in clinical practice: efficacy and safety.
Goldstein SR; Duvernoy CS; Calaf J; Adachi JD; Mershon JL; Dowsett SA; Agnusdei D; Stuenkel CA
Menopause; 2009; 16(2):413-21. PubMed ID: 19092711
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old.
Boonen S; McClung MR; Eastell R; El-Hajj Fuleihan G; Barton IP; Delmas P
J Am Geriatr Soc; 2004 Nov; 52(11):1832-9. PubMed ID: 15507059
[TBL] [Abstract][Full Text] [Related]
28. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint.
Marcus R; Wong M; Heath H; Stock JL
Endocr Rev; 2002 Feb; 23(1):16-37. PubMed ID: 11844743
[TBL] [Abstract][Full Text] [Related]
29. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis.
Harrington JT; Ste-Marie LG; Brandi ML; Civitelli R; Fardellone P; Grauer A; Barton I; Boonen S
Calcif Tissue Int; 2004 Feb; 74(2):129-35. PubMed ID: 14648009
[TBL] [Abstract][Full Text] [Related]
30. Strategies for treatment to prevent fragility fractures in postmenopausal women.
Geusens P
Best Pract Res Clin Rheumatol; 2009 Dec; 23(6):727-40. PubMed ID: 19945685
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
[TBL] [Abstract][Full Text] [Related]
32. [Drug treatment for the treatment of primary osteoporosis].
Halbekath J
Z Arztl Fortbild Qualitatssich; 2000 Aug; 94(6):453-60. PubMed ID: 10996934
[TBL] [Abstract][Full Text] [Related]
33. Evidence-based medicine and osteoporosis: a comparison of fracture risk reduction data from osteoporosis randomised clinical trials.
Meunier PJ
Int J Clin Pract; 1999 Mar; 53(2):122-9. PubMed ID: 10344048
[TBL] [Abstract][Full Text] [Related]
34. Antiresorption therapy and reduction in fracture susceptibility in the osteoporotic elderly patient: open study.
Muscoso E; Puglisi N; Mamazza C; Lo Giudice F; Testai M; Abbate S; Santangelo A; Panebianco P; Maugeri D
Eur Rev Med Pharmacol Sci; 2004; 8(2):97-102. PubMed ID: 15267123
[TBL] [Abstract][Full Text] [Related]
35. A review of combination regimens for osteoporosis--prevention and treatment.
Miller E; Kalin MF
Int J Fertil Womens Med; 2002; 47(5):198-204. PubMed ID: 12469706
[TBL] [Abstract][Full Text] [Related]
36. Role of bisphosphonates and calcitonin in the prevention and treatment of osteoporosis.
Woo T; Adachi JD
Best Pract Res Clin Rheumatol; 2001 Jul; 15(3):469-81. PubMed ID: 11485341
[TBL] [Abstract][Full Text] [Related]
37. The effect of alendronate therapy on osteoporotic fracture in the vertebral fracture arm of the Fracture Intervention Trial.
Black DM; Thompson DE
Int J Clin Pract Suppl; 1999 Apr; 101():46-50. PubMed ID: 12669740
[TBL] [Abstract][Full Text] [Related]
38. [Hormone replacement therapy and its derivatives in the prevention and treatment of osteoporosis].
Lamy O; Krieg MA
Rev Med Suisse Romande; 2002 Aug; 122(8):377-81. PubMed ID: 12357730
[TBL] [Abstract][Full Text] [Related]
39. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture.
Andrade SE; Majumdar SR; Chan KA; Buist DS; Go AS; Goodman M; Smith DH; Platt R; Gurwitz JH
Arch Intern Med; 2003 Sep; 163(17):2052-7. PubMed ID: 14504118
[TBL] [Abstract][Full Text] [Related]
40. Alendronate for fracture prevention in postmenopause.
Holder KK; Kerley SS
Am Fam Physician; 2008 Sep; 78(5):579-81. PubMed ID: 18788232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
